HC Wainwright Reiterates Buy Rating on Invivyd, Inc. (IVVD)

HC Wainwright's analyst maintains a buy rating for Invivyd, Inc. with a $10 price target.

Written by EarningsIQ · Published Jun 16, 2026, 2:05 AM EDT · Updated Jun 16, 2026, 3:01 PM EDT

Key Points

HC Wainwright reaffirmed its buy rating on Invivyd, Inc. (IVVD) with a $10 price target on June 15, 2026.
Invivyd, Inc. trades at $0.77 with a market cap of about $256 million and a 52-week range of $0.48 to $3.07.
Recent insider buying includes multiple purchases of 50,000 shares each by insiders on May 19, 2026.

HC Wainwright has reaffirmed its buy rating on Invivyd, Inc. (NasdaqGM: IVVD), maintaining a price target of $10. The update was made by analyst Patrick R. Trucchio on June 15, 2026. Shares of Invivyd traded at $0.77 following the announcement.

Invivyd, Inc. Stock Snapshot

Shares of Invivyd, Inc. currently trade at $0.77 on the NasdaqGM. The company has a market cap of approximately $256 million. Over the past 52 weeks, the stock has ranged from a low of $0.48 to a high of $3.07. It has a 50-day moving average of $1.32 and a 200-day moving average of $1.70. Invivyd's financial ratios show a current ratio of 6.47 and a quick ratio of 6.20, with a debt-to-equity ratio of 4.25.

Recent Earnings

Invivyd reported revenue of $55.9 million, with a revenue growth rate of 21.6%. However, the company posted a negative net margin of -138.9% and a return on equity of -60.3%. The next earnings report is expected on August 13, 2026.

Insider Buying and Selling at Invivyd, Inc.

Several insiders made significant purchases on May 19, 2026. Royan Ajay, Marc Elia, Kevin McLaughlin, Terrance McGuire, Tamsin Berry, and Paul Bolno each bought 50,000 shares. These transactions were not part of a planned trading program.

Analysts Set New Price Targets

On June 15, 2026, HC Wainwright reiterated its buy rating for Invivyd, Inc. with a price target of $10. BTIG also reaffirmed a buy rating with the same target earlier in the year. The analyst consensus remains strong buy, with an average target price of $10 based on three analyst opinions.

About Invivyd, Inc.

Invivyd, Inc., headquartered in New Haven, Connecticut, operates in the biotechnology sector. The company focuses on developing antibody therapies to prevent and treat viral infectious diseases. Its lead product, Pemivibart, is an investigational monoclonal antibody for COVID-19 prophylaxis. Invivyd is also working on other treatments for SARS-CoV-2 and respiratory viruses.

Bottom Line

HC Wainwright's reaffirmation of a buy rating signals confidence in Invivyd's potential, despite its current challenges. Investors keep an eye on such analyst updates, though it's important to remember that these ratings are based on past data and market conditions can change. Invivyd continues to develop its pipeline with several promising products in various stages.